Table 3.
Comparison between the non-high-dose and high-dose groups of patients after randomly matched analysis by using Greedy method
| Characteristic | Non-high-dose Group (n = 104) | High-dose Group (n = 104) | P-value |
|---|---|---|---|
| Age (years) | 65.6 ± 11.8 | 65.5 ± 13.9 | 0.258 |
| Female gender, n (%) | 24(23.1) | 39(37.5) | 0.024* |
| Creatinine(mg/dl) | 2.4 ± 2.3 | 2.8 ± 2.9 | 0.010* |
| Hb (g/L) | 88.9 ± 25.2 | 89.1 ± 27.6 | 0.386 |
| Platelet(× 109/L) | 191.5 ± 88.8 | 198.9 ± 106.3 | 0.113 |
| Use of NSAIDs, n (%) | 9(8.7) | 11(10.6) | 0.638 |
| Use of aspirin, n (%) | 15(14.4) | 18(17.3) | 0.569 |
| Use of clopidogrel, n (%) | 11(10.6) | 13(12.5) | 0.664 |
| Use of wafarin, n (%) | 6(5.8) | 10(9.6) | 0.298 |
| Shock at presentation | 52(50.0) | 65(62.5) | 0.069 |
| Coexisting illness, n (%) | |||
| CKDIII, IV/V | 40/14 (38.5/13.5) | 40/15(38.5/14.4) | 0.978 |
| COPD | 7(6.7) | 6 (5.8) | 0.775 |
| CAD | 19(18.3) | 28(26.9) | 0.136 |
| DM | 34(32.7) | 39(37.5) | 0.468 |
| CVA | 21(20.2) | 23(22.1) | 0.734 |
| Liver Cirrhosis | 20(19.2) | 14(13.5) | 0.261 |
| Rockall score | 6.4 ± 1.4 | 6.4 ± 1.4 | 1.000 |
| Time to endoscope (h) | 16.4 ± 20.3 | 16.9 ± 19.8 | 0.482 |
| PRBC BT(mL) | 1252.4 ± 1272.1 | 2156.3 ± 2117.1 | 0.007 |
| Ulcer size (cm) | 1.0 ± 0.6 | 0.9 ± 0.6 | 0.901 |
| Multiple ulcers, n (%) | 29(27.9) | 38(36.5) | 0.182 |
| Forrest classification Ia/Ib/IIa/IIb/IIc/III | 2/70/6/26/0/0 | 3/70/6/25/0/0 | 0.974 |
| Re-bleeding, n (%) | 14 (13.5) | 34 (32.7) | 0.001* |
| Surgery, n (%) | 2(1.9) | 1(1.0) | 0.561 |
| Hospital stay (days) | 13.9 ± 22.3 | 17.9 ± 15.3 | 0.641 |
| Mortality, n (%) | 10(9.6) | 16(15.4) | 0.403 |
| Bleeding related/Other causes | 4/6 | 8/8 | |
Abbreviation: Hb, hemoglobin; NSAID, nonsteriodal anti-inflammatory drug; CKD, chronic kidney disease; PPI, proton-pump inhibitor; DM, diabetes mellitus type 2; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CVA, cerebrovascular accident; BT, blood transfusion. * p < 0.05